{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:39:45Z","timestamp":1792024785088,"version":"4.4.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejmech.2026.118587","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:22:12Z","timestamp":1768350132000},"page":"118587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders"],"prefix":"10.1016","volume":"305","author":[{"given":"Seyed Ebrahim","family":"Alavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Boshrouyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aun","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Ebrahimi Shahmabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118587_bib1","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1111\/apt.17848","article-title":"Role of lifestyle and glucagon\u2010like peptide\u20101 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases","volume":"59","author":"Giannakogeorgou","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118587_bib2","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.3390\/ijms25073832","article-title":"Glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: novel medication in new liver disease nomenclature","volume":"25","author":"Chrysavgis","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118587_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1402583","article-title":"Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence","volume":"15","author":"Corrao","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.118587_bib4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1021\/acs.bioconjchem.1c00091","article-title":"Developing GLP-1 conjugated self-assembling nanofibers using copper-catalyzed alkyne\u2013azide cycloaddition and evaluation of their biological activity","volume":"32","author":"Alavi","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.118587_bib5","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1021\/acs.bioconjchem.0c00291","article-title":"Optimized methods for the production and bioconjugation of site-specific, alkyne-modified glucagon-like peptide-1 (GLP-1) analogs to azide-modified delivery platforms using copper-catalyzed alkyne\u2013azide cycloaddition","volume":"31","author":"Alavi","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.118587_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.4254\/wjh.v16.i5.731","article-title":"Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: opportunities and challenges","volume":"16","author":"Xie","year":"2024","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ejmech.2026.118587_bib7","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2026.118587_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2025.106159","article-title":"Role of glucagon-like Peptide-1 on amyloid, tau, and \u03b1-Synuclein: target engagement and rationale for the development in neurodegenerative disorders","volume":"173","author":"Au","year":"2025","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejmech.2026.118587_bib9","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1021\/acs.molpharmaceut.9b00308","article-title":"Glucagon-like peptide-1 receptor agonists and strategies to improve their efficiency","volume":"16","author":"Alavi","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.118587_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/jvim.70069","article-title":"Assessment of exenatide extended\u2010release for maintenance of diabetic remission in cats","volume":"39","author":"Gilor","year":"2025","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib12","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/dom.16154","article-title":"Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: current clinical landscape and perspectives","volume":"27","author":"Podobnik","year":"2025","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102064","article-title":"Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes","volume":"90","author":"Wu","year":"2024","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2026.118587_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib16","article-title":"The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment","volume":"16","author":"Sun","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118587_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13679-025-00623-1","article-title":"Dual and triple gut peptide agonists on the horizon for the treatment of type 2 diabetes and obesity. An overview of preclinical and clinical data","volume":"14","author":"Anastasiou","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.ejmech.2026.118587_bib18","doi-asserted-by":"crossref","first-page":"EJ25","DOI":"10.1507\/endocrj.EJ25-0087","article-title":"Physiology and clinical applications of GIP","volume":"72","author":"Yamane","year":"2025","journal-title":"Endocr. J."},{"key":"10.1016\/j.ejmech.2026.118587_bib19","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2026.118587_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118587_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2026.118587_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP)","volume":"95","author":"M\u00fcller","year":"2025","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib25","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s13300-024-01566-x","article-title":"Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes","volume":"15","author":"Gutgesell","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ejmech.2026.118587_bib26","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.drudis.2021.03.032","article-title":"GLP-1 peptide analogs for targeting pancreatic beta cells","volume":"26","author":"Alavi","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118587_bib27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118587_bib29","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Erratum. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-Week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2026.118587_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155848","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-finding study of survodutide (BI 456906) in people living with overweight\/obesity","volume":"153","author":"Le Roux","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2026.118587_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib34","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ejmech.2026.118587_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118587_bib37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13543784.2025.2472408","article-title":"The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines","volume":"34","author":"Madsbad","year":"2025","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2026.118587_bib38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.15333","article-title":"Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials","volume":"26","author":"Patel","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"A dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejmech.2026.118587_bib40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejmech.2026.118587_bib41","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.118587_bib42","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","article-title":"Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial","volume":"29","author":"Gao","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib43","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3390\/ijms26041651","article-title":"Focus on glucagon-like Peptide-1 target: drugs approved or designed to treat obesity","volume":"26","author":"Zhang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118587_bib44","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","volume":"400","author":"Urva","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118587_bib45","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2337\/db24-262-OR","article-title":"262-OR: pemvidutide, a GLP-1\/glucagon dual receptor agonist, in subjects with overweight or obesity\u2014a 48-week, placebo-controlled, phase 2 (MOMENTUM) trial","volume":"73","author":"Aronne","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2026.118587_bib47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejmech.2026.118587_bib48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose\u2013response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2026.118587_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1309118","article-title":"Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Nalisa","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.118587_bib50","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118587_bib51","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2\u00b7 4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejmech.2026.118587_bib52","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2026.118587_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon\u2010like peptide\u20101\/glucagon receptor co\u2010agonist JNJ\u201064565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose\u2010ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin Obes"},{"key":"10.1016\/j.ejmech.2026.118587_bib54","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/molecules28020751","article-title":"GLP-1R signaling and functional molecules in incretin therapy","volume":"28","author":"Wan","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118587_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.735019","article-title":"Striking the balance: GLP-1\/glucagon co-agonism as a treatment strategy for obesity","volume":"12","author":"Hope","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.118587_bib56","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/dom.13494","article-title":"A novel dual glucagon\u2010like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo\u2010controlled first\u2010in\u2010human and first\u2010in\u2010patient trials","volume":"21","author":"Tillner","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101801","article-title":"Results from three phase 1 trials of NNC9204-1177, a glucagon\/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity","volume":"78","author":"Friedrichsen","year":"2023","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib58","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/dom.15216","article-title":"The importance of glucose\u2010dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide","volume":"25","author":"Gasbjerg","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib59","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib60","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118587_bib61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.peptides.2017.12.021","article-title":"Gut hormone polyagonists for the treatment of type 2 diabetes","volume":"100","author":"Brandt","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2026.118587_bib62","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2026.118587_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107176","article-title":"A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis\u2013study design and rationale of HM-TRIA-201 study","volume":"130","author":"Abdelmalek","year":"2023","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.ejmech.2026.118587_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-025-01623-w","article-title":"GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation","volume":"17","author":"Movahednasab","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ejmech.2026.118587_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2025.171380","article-title":"Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities","volume":"187","author":"Bailey","year":"2025","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2026.118587_bib66","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/biomedicines12061320","article-title":"New developments in pharmacological treatment of obesity and type 2 Diabetes\u2014Beyond and within GLP-1 receptor agonists","volume":"12","author":"Sztanek","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118587_bib67","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib68","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/s42003-022-04242-7","article-title":"Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression","volume":"5","author":"Bomholt","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2026.118587_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102129","article-title":"A once-daily GLP-1\/GIP\/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans","volume":"96","author":"Finan","year":"2025","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2026.118587_bib70","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/cimb47040285","article-title":"The expanding role of GLP-1 receptor agonists: advancing clinical outcomes in metabolic and mental health","volume":"47","author":"Al","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118587_bib71","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial","volume":"397","author":"Mingrone","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118587_bib72","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: a review","volume":"324","author":"Arterburn","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.118587_bib73","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2337\/dc16-0030","article-title":"Development of early adiposity in infants of mothers with gestational diabetes mellitus","volume":"39","author":"Logan","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2026.118587_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon\u2010like peptide\u20101 receptor agonists and body habitus: a systematic review and meta\u2010analysis","author":"Berg","year":"2025","journal-title":"Obes. Rev."},{"key":"10.1016\/j.ejmech.2026.118587_bib75","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13300-023-01382-9","article-title":"Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes","volume":"14","author":"Palanca","year":"2023","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ejmech.2026.118587_bib76","first-page":"860","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ejmech.2026.118587_bib77","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41366-020-00694-1","article-title":"Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity","volume":"45","author":"Osinski","year":"2021","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejmech.2026.118587_bib78","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00228-021-03249-z","article-title":"Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study","volume":"78","author":"Guan","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118587_bib79","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12325-023-02761-1","article-title":"Glucagon-like peptide 1 (GLP-1) receptor variants and glycemic response to liraglutide: a pharmacogenetics study in Iranian people with type 2 diabetes mellitus","volume":"41","author":"Eghbali","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2026.118587_bib80","article-title":"Allelic variant in the glucagon\u2010like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: a pilot pharmacogenetics study","volume":"30","author":"Chedid","year":"2018","journal-title":"Neuro Gastroenterol. Motil."},{"key":"10.1016\/j.ejmech.2026.118587_bib81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41419-020-03366-0","article-title":"MicroRNA-194: a novel regulator of glucagon-like peptide-1 synthesis in intestinal L cells","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.118587_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/alz.089799","article-title":"Evaluation of novel GLP\u20101 analogue in the treatment of Alzheimer's disease","volume":"20","author":"Edison","year":"2024","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.ejmech.2026.118587_bib83","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.ejmech.2026.118587_bib84","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/cns.12404","article-title":"DPP\u20104 inhibitor linagliptin attenuates A\u03b2\u2010induced cytotoxicity through activation of AMPK in neuronal cells","volume":"21","author":"Kornelius","year":"2015","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejmech.2026.118587_bib85","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","article-title":"Brain metabolic dysfunction at the core of Alzheimer's disease","volume":"88","author":"de la Monte","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118587_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2025.107306","article-title":"Using nanostructured lipid carrier for the co-delivery of rifampicin and pentamidine for the treatment of cutaneous leishmaniasis","author":"Almutairy","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejmech.2026.118587_bib87","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-025-04120-8","article-title":"Redefining oropharyngeal cancer in the HPV era: integrating precision medicine and immunotherapeutic frontiers","author":"Alavi","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ejmech.2026.118587_bib88","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1080\/03639045.2025.2552392","article-title":"Use of nanoemulsion for co-delivery of silibinin and cabazitaxel for prostate cancer treatment","volume":"51","author":"Almutairy","year":"2025","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejmech.2026.118587_bib89","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12032-025-02603-w","article-title":"Enhanced antitumor efficacy of nanostructured lipid carrier co-loaded with docetaxel and 5-fluorouracil for targeted gastric cancer therapy","volume":"42","author":"Alyami","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2026.118587_bib90","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12032-025-02714-4","article-title":"Innovative PEGylated chitosan nanocarriers for co-delivery of doxorubicin and CpG in breast cancer therapy: preparation, characterization, and immunotherapeutic potential","volume":"42","author":"Alharthi","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2026.118587_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11274-025-04427-2","article-title":"Optimized solid lipid nanoparticles for co-delivery of gentamicin and doxycycline: a novel approach to combat intracellular brucella abortus infections","volume":"41","author":"Almutairy","year":"2025","journal-title":"World J. Microbiol. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.118587_bib92","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s13205-025-04443-x","article-title":"Nanoparticle-based drug delivery systems for non-surgical periodontal therapy: innovations and clinical applications","volume":"15","author":"Alavi","year":"2025","journal-title":"3 Biotech"},{"key":"10.1016\/j.ejmech.2026.118587_bib93","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s11095-024-03722-1","article-title":"Developing engineered nano-immunopotentiators for the stimulation of dendritic cells and inhibition and prevention of melanoma","volume":"41","author":"Alharthi","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2026.118587_bib94","article-title":"Enhancing the therapeutic landscape of cutaneous leishmaniasis: pegylated liposomal delivery of miltefosine for controlled release and improved efficacy","volume":"96","author":"Alharthi","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejmech.2026.118587_bib95","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12291-013-0325-0","article-title":"An investigation into the parameters affecting preparation of polybutyl cyanoacrylate nanoparticles by emulsion polymerization","volume":"29","author":"Ebrahimi","year":"2014","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.ejmech.2026.118587_bib96","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40291-025-00799-1","article-title":"Salivary biomarkers in periodontal disease: revolutionizing early detection and precision dentistry","volume":"29","author":"Alavi","year":"2025","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ejmech.2026.118587_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1456654","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery","volume":"4","author":"New","year":"2024","journal-title":"Front Drug Deliv"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T01:15:29Z","timestamp":1773537329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":97,"alternative-id":["S0223523426000322"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118587","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118587"}}